Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$79.33 USD

79.33
5,728,877

-2.48 (-3.03%)

Updated Aug 5, 2024 04:00 PM ET

After-Market: $79.34 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Indrajit Bandyopadhyay headshot

Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study

Spectrum Pharma (SPPI) amends poziotinib study protocol to include two cohorts to evaluate it in first-line lung cancer.

    Ekta Bagri headshot

    Immunotherapy for NSCLC: 4 Large-Cap Pharma Stocks in Focus

    Here we take a look at companies with approved immunotherapy therapies or pipeline candidates for the treatment of widely prevalent NSCLC.

      Pfizer's Drug Combo Betters Survival in Kidney Cancer Study

      Pfizer's (PFE) phase III study on a combination of its cancer drugs, Bavencio and Inlyta meets primary endpoint of improving PFS in advanced kidney cancer patients with PD-L1+ tumors.

        The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson

        The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson

          Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus

          Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.

            AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status

            AstraZeneca (AZN) and partner Amgen's asthma candidate, tezepelumab gets Breakthrough Therapy designation from the FDA.

              AstraZeneca Up This Year So Far on Favorable Pipeline Updates

              AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.

                AstraZeneca's Lupus Drug Misses Primary Endpoint in Study

                AstraZeneca's (AZN) phase III study, evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus, does not meet primary endpoint.

                  Kinjel Shah headshot

                  4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline

                  We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.

                    Bausch (BHC) Resubmits NDA for Duobrii for Plaque Psoriasis

                    Bausch Health Companies Inc. (BHC) resubmits its NDA for plaque psoriasis drug, Duobrii to the FDA and the agency has set a PDUFA action date of Feb 15, 2019.

                      AstraZeneca (AZN) Gets EU Nod for New Formulation of Bydureon

                      AstraZeneca (AZN) gains EU approval for a new formulation of its diabetes medicine Bydureon ??? Bydureon BCise.

                        Zacks.com headshot

                        Bausch (BHC) Gets FDA Approval for Altreno for Acne Vulgaris

                        Bausch (BHC) advances its dermatology portfolio with the FDA approval of Altreno for acne vulgaris.

                          Merck, Eisai Get EU Approval for Lenvima Label Expansion

                          Merck (MRK) and Japanese partner Eisai gain an approval from the EU for Lenvima label expansion. The anti-cancer drug receives the regulatory body's nod for first-line treatment of unresectable HCC.

                            AstraZeneca's Bevespi Unimpressive in Phase III COPD Study

                            AstraZeneca's (AZN) inhaler, Bevespi Aerosphere, fails to demonstrate superiority over Glaxo's Arono in a phase III COPD study.

                              Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs

                              Allergan (AGN) gets CRL for uterine fibroids candidate, Esmya. Merck (MRK) and Bristol-Myers' (BMY) PD-L1 inhibitors get FDA approval for expanded labels.

                                Novartis Breast Cancer Drug Meets Primary Goal in Phase III

                                Novartis' (NVS) late-stage candidate, BYL719, meets primary endpoint in SOLAR trial on advanced breast cancer patients.

                                  Ironwood's Linzess Gets Approval in Japan for New Indication

                                  Ironwood Pharmaceuticals (IRWD) along with its partner Astellas Pharma announces approval of Linzess in Japan for a new indication - chronic constipation.

                                    Japan Nods to AstraZeneca's Tagrisso for First-Line NSCLC

                                    AstraZeneca (AZN) receives approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the label expansion of Tagrisso.

                                      Merck, Eisai Get FDA Approval for Lenvima Label Expansion

                                      Merck (MRK) and Japanese partner Eisai gains an FDA approval for Lenvima label expansion. The anti-cancer drug receives the regulatory body's nod for the first line treatment of unresectable HCC.

                                        Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication

                                        Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.

                                          Mark Vickery headshot

                                          Top Research Reports for Cisco, AstraZeneca & Enbridge

                                          Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems (CSCO), AstraZeneca (AZN) and Enbridge (ENB).

                                            Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

                                            Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company announces restructuring initiative to improve operational efficiency.

                                              Here's Why Merck (MRK) Stock is Up Since Q2 Earnings Release

                                              Merck's (MRK) stock is up 4.2% since announcement of earnings in July. Let us have a look at the reasons for the same.

                                                The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

                                                The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers

                                                  Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus

                                                  Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.